Carryover negligibility and relevance in bioequivalence studies

Area of Science:

• Pharmaceutical Sciences
• Biostatistics
• Clinical Trial Design

Background:

• Carryover effects pose a significant challenge in pharmaceutical bioequivalence studies, potentially compromising the validity of study outcomes.
• Traditional null hypothesis testing for zero carryover is insufficient, failing to quantify the impact of existing carryover on study conclusions.

Purpose of the Study:

• To develop a more robust approach for evaluating carryover effects in average bioequivalence studies using 2x2 crossover designs.
• To address the issue of type I error inflation caused by carryover and to determine if carryover is negligible or significantly distorts study conclusions.

Main Methods:

• An equivalence testing framework is proposed to assess the relevance of carryover effects.
• Development of methods to define and quantify negligibility or relevance limits for carryover.

Main Results:

• The proposed equivalence testing approach offers a more consistent evaluation of carryover impact compared to traditional methods.
• Demonstration of the practical application of the proposed method using real-world bioequivalence study datasets.

Conclusions:

• The new approach provides a clearer understanding of carryover effect significance in bioequivalence studies.
• This method aids in making more informed decisions about study validity and drug approval, ensuring patient safety and therapeutic efficacy.